Skip to main content

Table 3 The comparison of clinicopathological characteristics and treatment outcomes in patients with dorsal and ventrolateral tongue leukoplakia (n = 111)

From: An anatomical perspective on clinicopathological characteristics and treatment outcomes of dorsal and ventrolateral tongue leukoplakia after carbon dioxide laser surgery

 

Dorsal tongue leukoplakia (n = 27)a

Ventrolateral tongue leukoplakia (n = 91)a

Odds ratio

P value

Clinicopathological data

Gender

   

0.81

 Female

7

27

1

 

 Male

20

64

0.83 (0.31–2.19)

 

Age

   

0.36

  < 65

25

77

1

 

  ≥ 65

2

14

2.27 (0.48–10.69)

 

Body mass index

24.83 ± 4.34

26.63 ± 4.88b

1.10 (0.99–1.22)

0.091

Alcohol drinking

   

0.17

 No

15

64

1

 

 Ex-drinkYes (ex-drinker or current drinker)

12

27

1.89 (0.78–4.58)

 

Smoking

   

0.38

 No

6

30

1

 

 Ex-smoker

10

23

0.46 (0.15–1.45)

 

 Current smoker

11

38

0.69 (0.23–2.08)

 

Betel quid chewing

   

0.27

 No

12

53

1

 

 Ex-chewer

14

31

0.50 (0.21–1.21)

 

 Current chewer

1

7

1.58 (0.18–14.12)

 

Diabetes mellitusc

   

0.78

 No

21

72

1

 

 Yes

4

19

1.39 (0.42–4.52)

 

Metformin takend

   

0.76

 No

22

73

1

 

 Yes

3

16

1.61 (0.43–6.03)

 

 Prevalence (%)e

3.39% [49 in (1591–147)]

9.53% [147 in (1591–49)]

2.81 (2.03–3.88)

< 0.001

Occurrence of leukoplakia in addition to tonguec

   

0.39

 No (single)

10

43

1

 

 Yes (multi-focal)

17

48

0.66 (0.27–1.59)

 

Candida infectiong

   

0.68

 No

26

84

1

 

 Yes

1

7

2.17 (0.25–18.43)

 

Morphological outlooks

   

1

 Homogeneous

20

66

1

 

 Non-homogeneous

7

25

1.08 (0.41–2.87)

 

 Area (cm2) of the lesion(s)h

1.47 ± 1.73

1.48 ± 1.47

1.01 (0.76–1.34)

0.96

Pathology

   

0.78

 Hyperplasia

8

27

1

 

 Mild dysplasia

15

42

0.69 (0.27–1.77)

 

 Moderate dysplasia

3

13

0.93 (0.26–3.27)

 

 Severe dysplasia / carcinoma in situ

1

9

0.55 (0.17–1.72)

 

Treatment outcomes

Postoperative recurrence

   

1

 No

24

78

1

 

 Yes

3

13

1.33 (0.35–5.07)

 

Postoperative malignant transformation

   

0.22

 No

25

89

1

 

 Yes

2

2

0.28 (0.04–2.10)

 

Cumulative malignant transformation rate

7.41%

2.25%

0.30 (0.04–2.16)

0.12

Time to develop malignant transformation (year)

3.19 ± 1.94

3.51 ± 2.12

1.16 (0.30–4.55)

0.83

Annual transformation ratei

2.32%

0.64%

0.28 (0.03–1.96)

0.099

Duration of follow-up (year)

4.41 ± 4.16

3.73 ± 4.35

0.97 (0.88–1.06)

0.47

  1. The bold values stand for P < 0.05
  2. aThere were 7 patients who had leukoplakia both on the dorsal and ventrolateral tongues
  3. bFour pieces of missing data in the group of body mass index of patients with ventrolateral tongue leukoplakia (n = 87)
  4. cTwo pieces of missing data in the group of diabetes mellitus (n = 116)
  5. dFour pieces of missing data in the group of metformin taken (n = 114)
  6. eThe prevalence of lesions is calculated by the number of tongue leukoplakia divided by that of all oral cavity leukoplakia in this study. There were totally 54 dorsal and 187 ventrolateral tongue leukoplakia lesions, including recurrent lesions
  7. fIf a patient has other sites of oral leukoplakia in addition to the tongue, the patient will be categorized as "Yes"
  8. gThe diagnosis of candida infection is made by pathology
  9. hIf the patient has more than 1 site of tongue leukoplakia, the area is the sum of all tongue leukoplakia lesions
  10. iThe annual transformation rate is calculated by the malignant transformation rate divided by the average time of development of carcinoma (year)
Back to article page

BMC Oral Health

ISSN: 1472-6831

Contact us